Tocilizumab Biosimilar (Destiny)

托珠单抗生物类似药 (德思特力)

Report date: 2025/11/10 20:01:49

Base Information

Drug NameTocilizumab Biosimilar (Destiny)
Drug Alias NameIA-001IA001
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonists
TargetsInterleukin-6 receptor alpha subunit
Therapy Area/IndicationsPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Destiny Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Destiny Biotech Co LtdLiaoning Great Kang Biological Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A